AnaptysBio Inc (ANAB) — Cash Flow-to-Debt Ratio
AnaptysBio Inc (ANAB) has a Cash Flow-to-Debt Ratio of 0.30x as of December 2025, meaning its operating cash flow of $98.00 Million could theoretically repay 0% of its total liabilities ($327.19 Million) in one year. See ANAB cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
AnaptysBio Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for AnaptysBio Inc across 13 annual periods. Also explore AnaptysBio Inc annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for AnaptysBio Inc (2013–2025)
Year-by-year debt coverage analysis for AnaptysBio Inc. For market capitalisation and broader financial context, see AnaptysBio Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | $19.70 Million | $327.19 Million | ▲ +118.4% |
| 2024 | -0.33x | $-135.34 Million | $412.97 Million | ▲ +1.2% |
| 2023 | -0.33x | $-120.80 Million | $364.29 Million | ▼ -56.9% |
| 2022 | -0.21x | $-73.59 Million | $348.28 Million | ▼ -31.9% |
| 2021 | -0.16x | $-45.92 Million | $286.64 Million | ▲ +77.6% |
| 2020 | -0.71x | $-14.16 Million | $19.82 Million | ▲ +69.0% |
| 2019 | -2.30x | $-69.52 Million | $30.19 Million | ▼ -7.4% |
| 2018 | -2.14x | $-48.51 Million | $22.63 Million | ▼ -140.2% |
| 2017 | -0.89x | $-19.44 Million | $21.78 Million | ▼ -126.4% |
| 2016 | -0.39x | $-9.03 Million | $22.91 Million | ▲ +43.2% |
| 2015 | -0.69x | $-9.67 Million | $13.94 Million | ▼ -190.6% |
| 2014 | 0.77x | $14.60 Million | $19.07 Million | ▲ +149.8% |
| 2013 | -1.54x | $-5.80 Million | $3.77 Million | — |